Immuneering reports 17.3-month survival in pancreatic cancer trial
Go back to Immuneering reports 17.3-month survival in pancreatic cancer trial| ImaRx Therapeutics, Inc. (NASDAQ: IMRX) | Delayed: 4.27 -0.3 (6.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.57 | 52 Week High | $0.04 | |||
| Open | $4.63 | 52 Week Low | $0.00 | |||
| Day High | $4.65 | P/E | N/A | |||
| Day Low | $4.24 | EPS | $-0.09 | |||
| Volume | 911,043 | |||||
| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 37.09 +0.74 (2.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.35 | 52 Week High | $66.55 | |||
| Open | $36.46 | 52 Week Low | $37.82 | |||
| Day High | $37.11 | P/E | N/A | |||
| Day Low | $36.06 | EPS | $0.00 | |||
| Volume | 2,855,412 | |||||
